Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AMETEK, Inc. (AME) vs Manhattan Associates Inc (MANH) Price & Performance

AMETEK, Inc.Trade
Manhattan Associates IncTrade

Price performance (Past 24H)

Key statistics

AMETEK, Inc. vs Manhattan Associates Inc — how do they compare? AMETEK, Inc. trades at $259.52 (market cap $58.76B), while Manhattan Associates Inc trades at $192.8 (market cap $11.38B). The key difference: AMETEK, Inc. is far larger — about 5.2× Manhattan Associates Inc's market cap, and AMETEK, Inc. pays a 0.53% dividend while Manhattan Associates Inc pays none. Which is the better fit depends on your goals.

AMEMANH
Market Cap
$58.76B$11.38B
Sector
IndustrialsTechnology
52-Week High
$256.30$220.19
52-Week Low
$179.28$120.88
Enterprise Value
$60.30B$11.25B
Dividend Yield
0.53%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AMETEK, Inc.

AME trades at $258.62, up 2.27% today, with a bullish technical signal and strong earnings momentum after beating Q2 2026 EPS estimates. The company reported record Q2 results and raised full-year guidance, supported by robust revenue growth and a 20.04% net income margin. Analysts maintain a consensus buy rating with a $281.86 price target, reflecting optimism about its 3D printing and electronics testing segments.

The outlook is positive given consistent earnings beats and upward guidance, but risks include high valuation multiples (P/E 37.47) and exposure to macroeconomic volatility. Institutional sentiment remains strong, with no sell ratings among 30 analysts, though the stock's proximity to resistance at $261 warrants caution for near-term entries.

Manhattan Associates Inc

MANH is trading at $192.63, down 1.56% on the day, with a bullish technical outlook supported by moving averages and strong momentum indicators. The company reported robust Q2 2026 earnings, beating EPS estimates with $1.39 versus $1.32 expected, driven by 26% cloud revenue growth. However, valuation ratios remain elevated with a P/E of 55.93 and P/B of 72.26, indicating high investor expectations. Recent news highlights an ongoing legal investigation into fiduciary duties by the Rosen Law Firm, creating a mixed sentiment backdrop.

The outlook for MANH is cautiously optimistic, with a consensus price target of $210.33 offering 9.2% upside potential. Key opportunities include sustained cloud growth and strong profitability metrics like a 96.38% ROE. Risks involve the high valuation, potential legal overhangs from the investigation, and any slowdown in enterprise software demand. Institutional analysts maintain an 80% buy rating, suggesting confidence in execution despite near-term headwinds.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AMETEK, Inc.

Ametek is a diversified industrial conglomerate with over $6 billion in sales. The firm operates through an electronic instruments group and an electromechanical group. EIG designs and manufactures differentiated and advanced instruments for the process, aerospace, power, and industrial end markets. EMG is a focused, niche supplier of highly engineered automation solutions, thermal management systems, specialty metals, and electrical interconnects, among other products. About half of the firm's sales are made in the United States. The firm's asset-light strategy in place for nearly two decades emphasizes growth through acquisitions, new product development through research and development, driving operational efficiencies, and global and market expansion.

Read more on AME

About Manhattan Associates Inc

Manhattan Associates, Inc. is a global leader in supply chain and omnichannel commerce software. The company provides a comprehensive suite of cloud-based and on-premise solutions for warehouse management (WMS), transportation management (TMS), and order management (OMS). MANH's technology helps retailers, wholesalers, and manufacturers manage inventory, optimize logistics, and unify the shopping experience across physical and digital channels.

Read more on MANH